SCA
STML

Secor Capital Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

Secor Capital Advisors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-31,719
Closed -$485K – 683
2018
Q1 		$485K Buy
+31,719
New +$494K 0.04% 379

Other funds holding STML

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Secor Capital Advisors's STML Position: Q2 2018 in Review

Secor Capital Advisors sold out of Stemline Therapeutics, Inc. (STML) in Q2 2018, closing a stake of 31,719 shares — an estimated $485K sold.

Secor Capital Advisors first reported a position in STML in Q1 2018 and held it in 1 quarter. The position peaked at $485K in Q1 2018. 91 funds tracked by Wall St. Rank hold STML as of Q2 2018.

  • Secor Capital Advisors reported no remaining Stemline Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Secor Capital Advisors sold 31,719 Stemline Therapeutics, Inc. shares in Q2 2018, an estimated $485K.
  • Secor Capital Advisors first reported a position in Stemline Therapeutics, Inc. in Q1 2018 and held it in 1 quarter.
  • Secor Capital Advisors's Stemline Therapeutics, Inc. position peaked at $485K in Q1 2018.
  • 91 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2018.

Based on Secor Capital Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.